Holen Sie sich die Stockscreener-App
21.31
0.15%
0.04
Schlusskurs vom Vortag:
$21.27
Offen:
$21.29
24-Stunden-Volumen:
2.10M
Relative Volume:
0.50
Marktkapitalisierung:
$2.20B
Einnahmen:
$133.67M
Nettoeinkommen (Verlust:
$-151.76M
KGV:
-14.35
EPS:
-1.4854
Netto-Cashflow:
$-124.86M
1W Leistung:
+0.48%
1M Leistung:
+87.67%
6M Leistung:
+199.17%
1J Leistung:
+144.84%
1-Tages-Spanne:
$21.26
$21.31
1-Wochen-Bereich:
$21.19
$21.43
52-Wochen-Spanne:
$5.635
$21.43
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Firmenname
Day One Biopharmaceuticals Inc
Sektor
Branche
Telefon
650 484-0899
Adresse
1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
Compare DAWN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
21.30 | 2.20B | 133.67M | -151.76M | -124.86M | -1.4854 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.30 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.20 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.47 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.53 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.27 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Fortgesetzt | TD Cowen | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-10-09 | Bestätigt | Needham | Buy |
| 2024-08-01 | Hochstufung | BofA Securities | Underperform → Buy |
| 2024-04-24 | Bestätigt | Needham | Buy |
| 2023-04-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-02-08 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-03 | Eingeleitet | Oppenheimer | Perform |
| 2022-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Buy |
| 2022-12-01 | Eingeleitet | BofA Securities | Buy |
Alle ansehen
Day One Biopharmaceuticals Inc Aktie (DAWN) Neueste Nachrichten
DAWN stock jumps 66% on $2.5B buyout offer from Servier - MSN
Servier Acquires Day One Biopharmaceuticals for $2.5B, Betting on Tovorafenib and the Pediatric Glioma Frontier - Oncodaily
Halper Sadeh LLC is Investigating Whether DAWN, SEM, EWCZ, FONR are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Are DAWN, TALK, UNF Obtaining Fair Deals for their Shareholders? – Company Announcement - Financial Times
The M&A Class Action Firm Encourages $hareholders to Contact Monteverde Concerning the Merger—DAWN, SEM, FONR, and EWCZ - Carroll County Mirror-Democrat
Day One Biopharmaceuticals gains amid takeover speculation - MSN
A Look At Day One Biopharmaceuticals (DAWN) Valuation After Recent Share Price Momentum - Yahoo Finance
Servier All Cash Deal Reframes Day One Biopharmaceuticals Valuation Story - simplywall.st
This VICI Properties Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday - Benzinga
Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Neutral" Rating at JPMorgan Chase & Co. - MarketBeat
JPMorgan downgrades Day One Biopharmaceuticals stock rating on Servier acquisition - Investing.com Canada
Servier to acquire Day One Biopharmaceuticals for $2.5 billion - Investing.com Nigeria
Day One Biopharmaceuticals Acquires Mersana Therapeutics: Key Financial Details, Purchase Price, and Pro Forma Impact - Minichart
This Day One Biopharmaceuticals Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
Day One Biopharmaceuticals' (DAWN) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat
Day One Biopharmaceutical (DAWN) Downgraded to Neutral by HC Wai - GuruFocus
Day One (DAWN) soars 100% on $2.5-billion merger - MSN
Are DAWN and TALK Obtaining Fair Deals for their Shareholders? - Finviz
Are DAWN and TALK Obtaining Fair Deals for their Shareholders? – Company Announcement - Financial Times
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now - TechStock²
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier - TradingView
DAWN Stock Downgraded by Wedbush with Price Target Adjustment | - GuruFocus
Wedbush Reaffirms Neutral Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals Touts OJEMDA Sales Surge, Sets $225M-$250M 2026 Outlook at TD Cowen - MarketBeat
Servier acquires International Biotech's Day One for USD2.5 billion - marketscreener.com
Day One (DAWN) Soars 100% on $2.5-Billion Merger - Yahoo Finance
Day One Biopharma Earnings Call Highlights Ojemda Surge - TipRanks
Top Small Cap Stocks To Add to Your WatchlistMarch 7th - MarketBeat
Key deals this week: Diana Shipping, Day One Biopharmaceuticals, Hudbay Minerals and more - Seeking Alpha
Pharmaceutical Stocks To ResearchMarch 7th - MarketBeat
JonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA Approval - MSN
Knott David M Jr Grows Position in Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Lowered to "Hold" at Wedbush - MarketBeat
Servier to acquire Day One Biopharmaceuticals for $2.5 billion By Investing.com - Investing.com Canada
Day One Biopharmaceuticals stock hits 52-week high at 21.12 USD - Investing.com Canada
Day One (DAWN) Climbs to 3-Year High on $2.5-Billion Merger - Yahoo Finance
Day One Biopharmaceuticals (DAWN) Stock Surges 66% on Servier's $2.5 Billion Acquisition Deal - International Business Times Australia
Servier to buy Day One Biopharma for $2.5 billion in tumor treatment push - ET Pharma
Servier Acquiring Day One Biopharmaceuticals For About $2.5 Billion - Pulse 2.0
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc.DAWN - Business Wire
User - The Chronicle-Journal
Day One Biopharmaceuticals, Inc. (DAWN): A Hold Rating Amid Emerging Potential - 富途牛牛
DAWN: Cowen Downgrades Day One Biopharmaceuticals to Hold March 2026 - Meyka
Servier Adds To Rare Cancers Portfolio With Proposed Day One Buyout - Citeline News & Insights
Day One Biopharmaceuticals (DAWN) Stock Jumps 66% After Servier Acquisition Deal - MEXC
DAWN Stock Quote Price and Forecast - CNN
JonesTrading Reiterates Hold Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - MarketBeat
Why A 'White Knight' Could Still Fight For Day One Bio - Investor's Business Daily
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN) - marketscreener.com
Day One Biopharmaceuticals (DAWN) Stock Soars 66% on Servier Buyout Agreement - MEXC
Finanzdaten der Day One Biopharmaceuticals Inc-Aktie (DAWN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):